Immunizations and Antibiotic Prophylaxis in Patients with Primary Immunodeficiency Diseases

Gülden PAÇACI ÇETİNa , Nida ÖZTOPb
aKocaeli City Hospital, Clinic of Immunology and Allergy Diseases, Kocaeli, Türkiye
bBaşakşehir Çam ve Sakura City Hospital, Clinic of Immunology and Allergy Diseases, İstanbul, Türkiye

Paçacı Çetin G, Öztop N. Immunizations and antibiotic prophylaxis in patients with primary immunodeficiency diseases. Çölkesen F, ed. Primary Immunodeficiency Diseases in Adults. 1st ed. Ankara: Türkiye Klinikleri; 2024. p.98-104.

ABSTRACT
Primary immunodeficiency diseases are characterized by disorders in the function of the immune system, increased susceptibility to infections, and a predisposition to autoimmune disease and malignancy. In most PID patients, antimicrobial prophylaxis and appropriate vaccination are crucial for prevention of infection. Live vaccines are generally not recommended for people with severe immunodeficiency. Live vaccines are generally not recommended for people with severe immunodeficiency, but may be administered in mild forms. Although inactivated vaccines are safe in primary immunodeficiency diseases, they are not expected to be effective enough in severe forms of antibody deficiency or in patients receiving immunoglobulin replacement therapy. In order to decrease the frequency and severity of infections, prophylactic antibiotic therapy is frequently used in the treatment of patients with primary immunodeficiency diseases. However, in some primary immunodeficiency diseases with more specific susceptibilities, prophylactic antiviral and/or antifungal therapy may also be required.

Keywords: Primary immunodeficiency diseases; vaccination; antibiotic prophylaxis

Referanslar

  1. Tangye SG, Al-Herz W, Bousfiha A, Cunningham-Rundles C, Franco JL, Holland SM, et al. Human Inborn Errors of Immunity: 2022 Update on the Classification from the International Union of Immunological Societies Expert Committee. J Clin Immunol. 2022;42(7):1473-507. [Crossref]  [PubMed]  [PMC]
  2. Bonilla FA, Khan DA, Ballas ZK, Chinen J, Frank MM, Hsu JT, et al.; Joint Task Force on Practice Parameters, representing the American Academy of Allergy, Asthma & Immunology; the American College of Allergy, Asthma & Immunology; and the Joint Council of Allergy, Asthma & Immunology. Practice parameter for the diagnosis and management of primary immunodeficiency. J Allergy Clin Immunol. 2015;136(5):1186-205.e1-78.
  3. Sobh A, Bonilla FA. Vaccination in Primary Immunodeficiency Disorders. J Allergy Clin Immunol Pract. 2016;4(6):1066-75. [Crossref]  [PubMed]
  4. Kuruvilla M, de la Morena MT. Antibiotic prophylaxis in primary immune deficiency disorders. J Allergy Clin Immunol Pract. 2013;1(6):573-82. [Crossref]  [PubMed]
  5. U.S. Department of Health and Human Services [Available from: [Link]
  6. Bonilla FA. Update: Vaccines in primary immunodeficiency. J Allergy Clin Immunol. 2018;141(2):474-81. [Crossref]  [PubMed]
  7. Canada Go. Immunization of immunocompromised persons: Canadian immunization guide. 2020.
  8. Shaghaghi M, Parvaneh N, Ostad-Rahimi P, Fathi SM, Shahmahmoodi S, Abolhassani H, et al. Combined immunodeficiency presenting with vaccine-associated paralytic poliomyelitis: a case report and narrative review of literature. Immunol Invest. 2014;43(3):292-8. [Crossref]  [PubMed]
  9. Patel NC, Hertel PM, Estes MK, de la Morena M, Petru AM, Noroski LM, et al. Vaccine-acquired rotavirus in infants with severe combined immunodeficiency. N Engl J Med. 2010;362(4):314-9. [Crossref]  [PubMed]  [PMC]
  10. Yeganeh M, Heidarzade M, Pourpak Z, Parvaneh N, Rezaei N, Gharagozlou M, et al. Severe combined immunodeficiency: a cohort of 40 patients. Pediatr Allergy Immunol. 2008;19(4):303-6. [Crossref]  [PubMed]
  11. Al-Sukaiti N, Reid B, Lavi S, Al-Zaharani D, Atkinson A, Roifman CM, et al. Safety and efficacy of measles, mumps, and rubella vaccine in patients with DiGeorge syndrome. J Allergy Clin Immunol. 2010;126(4):868-9. [Crossref]  [PubMed]
  12. American Academy of Pediatrics. Immunization and other considerations in immunocompromised children. In: Kimberlin DW, Barnett ED, Lynfield R, Sawyer MH, eds. Red Book: 2021-2024 Report of the Committee on Infectious Diseases. American Academy of Pediatrics, Itasca, IL 2021. p.72.
  13. Hanitsch LG, Löbel M, Mieves JF, Bauer S, Babel N, Schweiger B, et al. Cellular and humoral influenza-specific immune response upon vaccination in patients with common variable immunodeficiency and unclassified antibody deficiency. Vaccine. 2016;34(21):2417-23. [Crossref]  [PubMed]
  14. Finelli L, Fiore A, Dhara R, Brammer L, Shay DK, Kamimoto L, et al. Influenza-associated pediatric mortality in the United States: increase of Staphylococcus aureus coinfection. Pediatrics. 2008;122(4):805-11. [Crossref]  [PubMed]
  15. Medical Advisory Committee of the Immune Deficiency Foundation; Shearer WT, Fleisher TA, Buckley RH, Ballas Z, Ballow M, Blaese RM, et al. Recommendations for live viral and bacterial vaccines in immunodeficient patients and their close contacts. J Allergy Clin Immunol. 2014;133(4):961-6. [Crossref]  [PubMed]  [PMC]
  16. Arciuolo RJ, Jablonski RR, Zucker JR, Rosen JB. Effectiveness of Measles Vaccination and Immune Globulin Post-Exposure Prophylaxis in an Outbreak Setting-New York City, 2013. Clin Infect Dis. 2017;65(11):1843-7. [Crossref]  [PubMed]
  17. SeyedAlinaghi S, Karimi A, Barzegary A, Mojdeganlou H, Vahedi F, Mirghaderi SP, et al. COVID-19 mortality in patients with immunodeficiency and its predictors: a systematic review. Eur J Med Res. 2022;27(1):195. [Crossref]  [PubMed]  [PMC]
  18. Prevention CfDCa. Centers for Disease Control and Prevention. Interim Clinical Considerations for Use of COVID-19 Vaccines Currently Authorized in the United States [Available from: Available at:(Accessed on December 8,2023) [Link]
  19. Aguilar C, Malphettes M, Donadieu J, Chandesris O, Coignard-Biehler H, Catherinot E, et al. Prevention of infections during primary immunodeficiency. Clin Infect Dis. 2014;59(10):1462-70. [Crossref]  [PubMed]
  20. Segundo GRS, Condino-Neto A. Treatment of patients with immunodeficiency: Medication, gene therapy, and transplantation. J Pediatr (Rio J). 2021;97 Suppl 1(Suppl 1):S17-S23. [Crossref]  [PubMed]  [PMC]
  21. Ballow M, Paris K, de la Morena M. Should Antibiotic Prophylaxis Be Routinely Used in Patients with Antibody-Mediated Primary Immunodeficiency? J Allergy Clin Immunol Pract. 2018;6(2):421-6. [Crossref]  [PubMed]
  22. Milito C, Pulvirenti F, Cinetto F, Lougaris V, Soresina A, Pecoraro A, et al. Double-blind, placebo-controlled, randomized trial on low-dose azithromycin prophylaxis in patients with primary antibody deficiencies. J Allergy Clin Immunol. 2019;144(2):584-593.e7. [Crossref]  [PubMed]
  23. Kartal Ö. Yaygın Değişken İmmün Yetmezlik. Türkiye Klinikleri J Immun Allergy-Special Topics. 2017;10(2):64-71.